Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BerGenBio ASA ( (BRRGF) ) has issued an announcement.
BerGenBio ASA has announced a fully underwritten rights issue to raise approximately NOK 130 million following its merger with Oncoinvest ASA. This strategic move aims to strengthen the company’s financial position and support its continued growth and development in the biotechnology sector, with the rights issue subject to various conditions including regulatory approvals and the completion of the merger.
The most recent analyst rating on (BRRGF) stock is a Buy with a NOK38.00 price target. To see the full list of analyst forecasts on BerGenBio ASA stock, see the BRRGF Stock Forecast page.
More about BerGenBio ASA
BerGenBio ASA is a biotechnology company focused on developing innovative drugs for aggressive diseases, primarily in the field of oncology. The company is known for its research and development of targeted therapies aimed at treating cancer and other serious conditions.
YTD Price Performance: -83.01%
Average Trading Volume: 308,039
Current Market Cap: NOK54.33M
Learn more about BRRGF stock on TipRanks’ Stock Analysis page.